
Pharmaceutical Companies and the Opioid Crisis
In a new Investor Brief published by the Investors for Opioid & Pharmaceutical Accountability (IOPA), new research outlines the realities of executive accountability at pharmaceutical companies, and why lawsuits have little impact on executive compensation.
View PDF